Brain47Brain47Join Brain47
0A2V

Sanofi

Healthcare · USD · NASDAQ

SNYT212

Price

$44.41

-0.20%

Cap

$96.29B

Earnings

—

30d Trend

+6.5%

0A2V
Loading chart data...
0 days · % change from startPowered by Brain47
Next earnings:2026-07-30

BRAIN47 SIGNAL

0
MODERATE
Risk Level41
Quality71
Momentum35
Technical61
Fundamentals41

Raw weighted: 52×Macro 0.99 (−1%)=51

RISK

41/100
90d Volatility
24.0%Moderate
ATR %
4.8%High daily moves
Max Drawdown (1Y)
-16.7%Normal

QUALITY

71/100
ROE (avg)
6.6%Weak
Piotroski F-Score
7/9Strong
Margin Stability
CV 1.8%Very stable
Accruals
-2.3%Cash earnings
Interest Coverage
15.3xVery comfortable

MOMENTUM

35/100
12-1M Momentum
-12.3%Strong downtrend
6-1M Momentum
-8.4%Negative
1M Return
+6.7%Strong recent gains

TECHNICAL

61/100
RSI (14)
60.5Neutral
Price vs SMA200
+2.1%Bullish trend
MACD
+0.18Bullish momentum
Bollinger Band
82%Near upper band
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.281Noisy/choppy

FUNDAMENTALS

41/100
P/S
2.4Fair
PEG
3.97Overpriced growth

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months ★55
3-12 months51
1-5+ years53

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate Sanofi at 51/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is quality at 71/100. I classify this as a defensive position with the strongest thesis on a short-term horizon.

DETAILED ANALYSIS

Limited short-term thesis. Quality (71) and Technical (61) are the primary strengths. I note that momentum is the weakest area at 35/100 — this warrants monitoring. I classify this as a defensive holding — stability characteristics and high business quality provide portfolio ballast.

defensiveScore: 51/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.